Cadaver Skin Injections Spark Ethical Debate in Cosmetic Industry Boom

A new type of facial treatment using donated human tissue has entered the cosmetic market. Known as ECM boosters, these injections rely on processed cadaver skin to rejuvenate ageing faces. While the industry grows rapidly, ethical and regulatory concerns have already surfaced. L&C Bio introduced the first major domestic ECM product, Ellavie Rituo, in 2024. The treatment uses acellular dermal matrix—a powder derived from donated skin—dissolved in saline and injected into the face. Unlike alternatives such as Rejuran, which triggers collagen production with salmon DNA, ECM boosters directly implant collagen, elastin, and hyaluronic acid to restore skin structure.

A single session costs around $370. However, market expansion faces a key challenge: supply, not demand, determines success. Sourcing and processing human tissue limits production capacity, creating a bottleneck for wider availability.

Competitors have quickly emerged. MS Bio and Hans Biomed now offer similar ECM products in Korea, while Renuva is already available in the US. Yet, the regulatory landscape remains uncertain. Some experts argue that stricter clinical trials should be required before these treatments become mainstream. The global cosmetic injectable market is forecast to reach $38.8 billion by 2034, growing at over 10% annually. ECM boosters represent a small but controversial segment of this expansion. As demand rises, debates over ethics, regulation, and material sourcing will shape the future of these human tissue-based treatments.